FDA Panel Votes Against Amgen's Xgeva For Prostate Cancer

Law360, New York (February 8, 2012, 8:04 PM EST) -- A U.S. Food and Drug Administration advisory committee on Wednesday recommended against approving Amgen Inc.'s bone cancer drug Xgeva for patients with prostate cancer that has not spread to the bones.

The FDA's Oncologic Drugs Advisory Committee, made up of nonagency medical officials, voted 12 to 1 to reject Amgen's proposal to allow Xgeva for treatment of men with recurring prostate cancer who are at high risk of developing bone cancer, according to the company. The FDA is not required to adopt the recommendations of its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.